News | Wearables | February 21, 2023

AliveCor Announces the ITC’s Limited Exclusion Order Against Apple Clears Presidential Review

Sets stage for enforcement of LEO barring Apple from importing Apple watches that infringe on AliveCor patents into the U.S. for sale


February 21, 2023 — AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced that the Final Determination ruling issued by the U.S. International Trade Commission (ITC), which imposed a Limited Exclusion Order (LEO) and a cease and desist order on Apple Watches infringing on AliveCor patents, has cleared Presidential review. This is the Commission’s first LEO against Appleto clear Presidential review, and sends a strong signal to innovative companies that their IP is protected within the legal framework.  

The ITC’s ruling in December affirmed that Apple infringed AliveCor’s groundbreaking intellectual property. The LEO will go into effect upon favorable resolution of appeals in the case, including AliveCor’s appeal of the U.S. Patent Trial and Appeal Board’s decision.  

“We applaud President Biden for upholding the ITC's ruling and holding Apple accountable for infringing the patents that underpin our industry-leading ECG technology,” said Priya Abani, CEO of AliveCor. “This decision goes beyond AliveCor and sends a clear message to innovators that the US will protect patents to build and scale new technologies that benefit consumers.”

Beyond the successful patent infringement ruling with the ITC, AliveCor continues to hold Apple accountable for its anticompetitive behavior through its antitrust case in the Northern District of California, which is expected to go to trial in early 2024. 

For more information: www.alivecor.com 

Related Wearable ECG Monitoring Content:  

ITC Rules Apple Violated AliveCor’s Patents 

How Advances in Wearable Cardiac Monitors Improve the Patient and Clinician Experience  

Longer Continuous Ambulatory Cardiac Monitoring Enables More Comprehensive Evaluation of Atrial Fibrillation  

Cardea Solo Wearable ECG Collects High-altitude Cardiac Data on Denali Expedition  

Cardiac Insight Partners With VivoSense for Cardiovascular Research  

Wearable Cardiac Monitors Are Effective for Tracking Atrial Fibrillation Following Ablation  

As Interpretation Criteria Evolve, False Positive Athlete ECG Screening Rates Can Decrease 


Additional Content

News | Cardiac Diagnostics

March 4, 2026 — Inflo Health has launched a comprehensive cardiology suite designed to address care management gaps ...

Home March 04, 2026
Home
News | Cardiac Diagnostics

Feb. 26, 2026 — Eko Health has partnered with Wayne General Hospital in Wayne County, Mississippi, to deploy SENSORA, an ...

Home February 26, 2026
Home
News | Cardiac Diagnostics

Nov. 12, 2025 — AISAP, a provider of AI Point-of-Care Diagnostics, has announced a field initiative in Ghana, deploying ...

Home November 12, 2025
Home
News | Cardiac Diagnostics

June 11, 2025 — MorningStar Laboratories, LLC, a developer of precision diagnostic tests that address unmet clinical ...

Home June 16, 2025
Home
News | Cardiac Diagnostics

Aug. 13, 2024 – The traditional lipid panel may not give the full picture of cholesterol-related heart disease risk for ...

Home August 15, 2024
Home
Subscribe Now